

Product Datasheet

CCR4 Antibody (KW-0761 (Mogamulizumab)) - BSA Free NBP2-81269-0.1mg

Unit Size: 0.1 mg

Store at 4C for up to 3 months. For longer storage, aliquot and store at -20C.

www.novusbio.com



technical@novusbio.com

Protocols, Publications, Related Products, Reviews, Research Tools and Images at:
www.novusbio.com/NBP2-81269

Updated 4/20/2025 v.20.1

Earn rewards for product
reviews and publications.

Submit a publication at www.novusbio.com/publications

Submit a review at www.novusbio.com/reviews/destination/NBP2-81269



NBP2-81269-0.1mg

CCR4 Antibody (KW-0761 (Mogamulizumab)) - BSA Free

Product Information	
Unit Size	0.1 mg
Concentration	1 mg/ml
Storage	Store at 4C for up to 3 months. For longer storage, aliquot and store at -20C.
Clonality	Monoclonal
Clone	KW-0761 (Mogamulizumab)
Preservative	0.02% Proclin 300
Isotype	IgG1 Kappa
Purity	Protein A purified
Buffer	PBS
Product Description	
Host	Human
Gene ID	1233
Gene Symbol	CCR4
Species	Human
Specificity/Sensitivity	This antibody is specific for human CCR4, a chemokine receptor that is preferentially expressed by Th2 and regulatory T (Treg) cells. CCR4 is also detected on basophils, platelets, monocytes and brain microvascular and coronary artery endothelial cells.
Immunogen	This antibody was prepared by humanization of a mouse anti-CCR4 mAb.
Product Application Details	
Applications	Functional
Recommended Dilutions	Functional
Application Notes	This reformatted human antibody was made using the variable domain sequences of the original human IgG1 (fucosylated) format, for improved compatibility with existing reagents, assays and techniques. This antibody is not additionally fucosylated. The clinically used format of this antibody (which underwent additional de-fucosylation to increase antibody-dependent cellular cytotoxicity (ADCC)), has significant clinical activity in heavily pretreated patients with mycosis fungoides and Sezary syndrome, and is associated with an overall response rate of 36.8% and a median duration of response of 10.4 months (Duvic et al, 2014). It was shown to CCR4-expressing cells by antibody-dependent, cell-mediated cytotoxicity (ADCC). Therapeutically, this results in a dual mechanism of action; in addition to directly targeting malignant T cells over-expressing CCR4, this antibody also depletes T reg cells, an important therapeutic target in human cancers. This antibody is well-tolerated, and administration does not appear to trigger clinically significant autoimmune complications in phase 1/2 trials (Duvic et al, 2014). This antibody has been approved in Japan for the treatment of relapsed or refractory adult T-cell leukemia/lymphoma, and is in clinical trials for solid cancers.





Novus Biologicals USA

10730 E. Briarwood Avenue
Centennial, CO 80112
USA
Phone: 303.730.1950
Toll Free: 1.888.506.6887
Fax: 303.730.1966
nb-customerservice@bio-techne.com

Bio-Techne Canada

21 Canmotor Ave
Toronto, ON M8Z 4E6
Canada
Phone: 905.827.6400
Toll Free: 855.668.8722
Fax: 905.827.6402
canada.inquires@bio-techne.com

Bio-Techne Ltd

19 Barton Lane
Abingdon Science Park
Abingdon, OX14 3NB, United Kingdom
Phone: (44) (0) 1235 529449
Free Phone: 0800 37 34 15
Fax: (44) (0) 1235 533420
info.EMEA@bio-techne.com

General Contact Information

www.novusbio.com
Technical Support: nb-technical@bio-techne.com
Orders: nb-customerservice@bio-techne.com
General: novus@novusbio.com

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

For more information on our 100% guarantee, please visit www.novusbio.com/guarantee

Earn gift cards/discounts by submitting a review: www.novusbio.com/reviews/submit/NBP2-81269

Earn gift cards/discounts by submitting a publication using this product:
www.novusbio.com/publications

